Division of Endocrinology, Department of Internal Medicine, Metabolic Diseases Institute, University of Cincinnati Cincinnati, OH, USA.
Front Endocrinol (Lausanne). 2011 Nov 2;2:67. doi: 10.3389/fendo.2011.00067. eCollection 2011.
Ghrelin, a stomach-derived, secreted peptide, and its receptor (growth hormone secretagogue receptor, GHSR) are known to modulate food intake and energy homeostasis. The ghrelin system is also expressed broadly in cardiovascular tissues. Since ghrelin has been associated with anti-inflammatory and anti-atherogenic properties, but is also well known to promote obesity and impair glucose metabolism, we investigated whether ghrelin has any impact on the development of atherosclerosis. The hypothesis that endogenous ghrelin signaling may be involved in atherosclerosis has not been tested previously.
We crossed ghrelin receptor knockout mice (GHSr(-/-)) into a low-density lipoprotein receptor-null (Ldlr(-/-)) mouse line. In this model, atherosclerotic lesions were promoted by feeding a high-fat, high-cholesterol Western-type diet for 13 months, following a standard protocol. Body composition and glucose homeostasis were similar between Ldlr(-/-) and Ldlr/GHSR(-/-)ko mice throughout the study. Absence or presence of GHSr did not alter the apolipoprotein profile changes in response to diet exposure on an LDLRko background. Atherosclerotic plaque volume in the aortic arch and thoracic aorta were also not affected differentially in mice without ghrelin signaling due to GHSR gene disruption as compared to control LDLRko littermates. In light of the associations reported for ghrelin with cardiovascular disease in humans, the lack of a phenotype in these loss-of-function studies in mice suggests no direct role for endogenous ghrelin in either the inhibition or the promotion of diet-induced atherosclerosis.
These data indicate that, surprisingly, the complex and multifaceted actions of endogenous ghrelin receptor mediated signaling on the cardiovascular system have minimal direct impact on atherosclerotic plaque progression as based on a loss-of-function mouse model of the disease.
胃泌素,一种源自胃的分泌肽及其受体(生长激素促分泌素受体,GHSR),已知可调节摄食和能量稳态。胃泌素系统也广泛表达于心血管组织中。由于胃泌素与抗炎和抗动脉粥样硬化特性有关,但也众所周知会促进肥胖和损害葡萄糖代谢,我们研究了胃泌素是否对动脉粥样硬化的发展有任何影响。内源性胃泌素信号可能参与动脉粥样硬化的假设以前尚未得到检验。
我们将胃泌素受体敲除小鼠(GHSr(-/-))与低密度脂蛋白受体缺失(Ldlr(-/-))小鼠系杂交。在这种模型中,通过喂养高脂肪、高胆固醇的西方饮食 13 个月来促进动脉粥样硬化病变的发生,遵循标准方案。在整个研究过程中,Ldlr(-/-)和 Ldlr/GHSR(-/-)ko 小鼠的体成分和葡萄糖稳态相似。在 LDLRko 背景下,GHSr 的存在或不存在均不会改变饮食暴露时的载脂蛋白谱变化。由于缺乏 GHSR 基因,与对照 LDLRko 同窝仔鼠相比,缺乏胃泌素信号的小鼠的主动脉弓和胸主动脉中的动脉粥样硬化斑块体积也没有差异。鉴于人类报告的胃泌素与心血管疾病的相关性,这些缺失功能研究中缺乏表型表明,内源性胃泌素受体介导的信号在抑制或促进饮食诱导的动脉粥样硬化方面没有直接作用。
这些数据表明,令人惊讶的是,内源性胃泌素受体介导的信号在心血管系统中的复杂和多方面作用对基于疾病的缺失功能小鼠模型的动脉粥样硬化斑块进展几乎没有直接影响。